The WHO estimates the average medication adherence rate is 50% in developed nations, though the U.S. trails other countries in reported adherence on Medisafe.…


Celgene heaps pressure on MS pills as blockbuster hopeful ozanimod hits its marks

Gilenya-maker Novartis features more MS patients in new online dictionary tools

Patient requests buoy oral meds from Biogen, Novartis in crowded MS market

Tecfidera, Gilenya and Aubagio's 3-way battle for MS share is about to heat up

Novartis could snag a blockbuster MS market all for itself, just in time to fight Gilenya generics

As Tecfidera lags, Biogen hopes real-world data can help keep patients on their meds

Roche's MS hopeful Ocrevus banks more data for fierce market-share combat

SCOTUS backs biopharma's most-hated patent challenges